Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Dova Pharmaceuticals, Inc.

Case Summary

Dova Pharmaceuticals, Inc. Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 10/18/2019 (Date of last review)

Filing Date: October 18, 2019

According to the Complaint, Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, with an initial
focus on addressing thrombocytopenia.

This action stems from a proposed transaction announced on September 30, 2019, pursuant to which Dova Pharmaceuticals, Inc. will be acquired by Swedish Orphan Biovitrum AB (publ).

On September 30, 2019, Dova’s Board of Directors caused the Company to enter into an agreement and plan of merger with Sobi. Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer to purchase all of Dova’s outstanding common stock for $27.50 in cash plus one contingent value right per share, which represents the right to receive $1.50 per share. The Tender Offer is set to expire on November 8, 2019.

On October 11, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

Company & Securities Information

Defendant: Dova Pharmaceuticals, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: DOVA
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Earl M. Wheby, Jr., et al. v. Dova Pharmaceuticals, Inc., et al.

COURT: D. Delaware
DOCKET #: 19-CV-01981
JUDGE: Hon. Leonard P. Stark
DATE FILED: 10/18/2019
CLASS PERIOD START: 09/30/2019
CLASS PERIOD END: 10/18/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Rigrodsky & Long, P.A. (Wilmington)
  2. RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Complaint for Violation of the Securities Exchange Act of 1934 10/18/2019
2 U.S. District Court Civil Docket 10/18/2019

Reference Complaint

—Reference Complaint Complaint Related Data is not available

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases